Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28078
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 游若? | |
dc.contributor.author | Pei-Jiuan Chyou | en |
dc.contributor.author | 邱佩娟 | zh_TW |
dc.date.accessioned | 2021-06-13T00:00:49Z | - |
dc.date.available | 2017-12-31 | |
dc.date.copyright | 2007-08-03 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-30 | |
dc.identifier.citation | 參考文獻
李福臨:乳酸菌分類之研究近況。食品工業,32(8): 36-42 (2000)。 林國暉:乳酸發酵蔬菜萃取物對4-nitroquinoline N-oxide基因毒性及數株癌細胞抑制之研究。國立臺灣大學食品科技研究所碩士論文(2006)。 沈明來:試驗設計學。九州圖書文物有限公司,臺北,臺灣(2000) 。 紀玉霜:不同工作週期之低能量超音波刺激在體外對纖維母細胞的影響。私立中原大學醫學工程學系碩士論文(2003)。 翁麗華:攝食複合乳酸菌粉及優酪乳對健康成人腸道菌相及致突變性之影響。國立臺灣大學食品科技研究所碩士論文(2006)。 張勝善:牛乳與乳製品。長河出版社,臺北,臺灣(1983) 。 傅麒玲:腸道菌相與腸道免疫功能的評估辦法。食品工業,31(12): 14-25 (1999)。 程金燕:由改善腸胃道的功能來探討機能性食品的功效。食品工業,32(6): 48-65 (2000)。 黃瓊萱:雙叉桿菌之特性及其利用。食品工業,24(12): 35-40 (1992)。 廖啟成:比菲德氏菌在食品產業的應用與發展。食品工業,29(6): 1-4 (1997)。 衛生署:健康食品之胃腸功能改善評估方法。行政院衛生署公告衛署食字第0920401629號,臺北,臺灣(2003)。 鄭安平:攝食益生菌奶粉對健康成人腸道菌之影響。國立臺灣大學食品科技研究所碩士論文(2002)。 鄭妃彣:薏苡麩皮甲醇萃取物之細胞毒性成分分離與純化。國立臺灣大學食品科技研究所碩士論文(2006)。 顏文俊:腸內菌群與人體健康。食品工業,23(9): 46-52 (2000)。 Akalin AS, Fenderya S, Akbulut N. 2004. Viability and activity of bifidobacteria in yogurt containing fructooligosaccharide during refrigerated storage. Int J Food Sci Technol 39: 613-621. Alberts DS, Einspahr J, Rees-McGee S, Ramanujam P, Buller MK, Clark L, Ritenbaugh C, Atwood J, Pethigal P, Earnest D, Villar H, Phelps J, Lipkin M, Wargvich M, Meyskens FL. 1990. Effects of dietary wheat bran fiber on rectal epithelial cell proliferation in patients with research for colorectal cancers. J Natl Cancer Inst 82: 1280. AOAC. 1990. Official Methods of Analysis. 15th edition. Association of Official Analytical Chemists, Washington, DC. Arunachalam KD. 1999. Role of bifidobacteria in nutrition, medicine and technology. Nutr Res 19: 1559-1597. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. 2005. Host-bacterial mutualism in the human intestine. Science 307: 1915-1920. Bae EA, Han MJ, Song M, Kim DH. 2002. Purification of rotavirus infection-inhibitory protein from Bifidobacterium breve K-110. Food Microbiol Biotechnol 12: 553-556. Barbut F, Kajzer C, Planas N, Petit JC. 1993. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 31: 963-967. Barero GJ, Runge G, Fisher D, Crawford MN, Torres FE, Gyorgy P. 1952. Investigation the bacterial flora, pH and sugar content in the intestinal tact of infants. J Pediatr 40: 152-163. Bartram HP, Scheppach W, Gerlach S, Ruckdeschel G, Kelber E, Kasper H. 1994. Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in healthy subjects? Am J Clin Nutr 59: 428-432. Beaugerie L, Petit JC. 2004. Microbiol-gut interactions in health and disease. Antibiotic-associated diarrhea. Best Pract Res Clin Gastroenterol 18: 337-352. Bengmark S. 1998. Probiotics and prebiotics in prevention and treatment of gastrointestinal diseases. Gastroenterol Int 11: 4-7. Benno Y, Mitsuoka T. 1992. Impact of Bifidobacterium longum on human fecal microflora. Microbiol Immuno 36: 683-694. Bingham SA, Pignatelli P, Pollock JRA. 1996. Dose increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? Carcinogenesis 17: 515-523. Blaut M, Braune A, Wunderlich S, Sauer P, Schneider H, Glatt H. 2006. Mutagenicity of arbutin in mammalian cells after activation by human intestinal bacteria. Food Chem Toxicol 44: 1940-1947. Bolduc MP, Raymond Y, Fustier P, Champagne CP, Vuillemard JC. 2006. Sensitivity of bifidobacteria to oxygen and redox potential in non-fermented pasteurized milk. Int Dairy J 16: 1038-1048. Botsford JL, Desmoss RD. 1972. Escherichia coli tryptophanase in the enteric environment. J Bacteriol 109: 74-80. Bruce WR. 1987. Recent hypotheses for the origin of colon cancer. Cancer Res 47: 4237-4242. Brynestad S, Granum PE. 2002. Clostridium perfringens and foodborne infections. Int J Food Microbiol 74: 195-202. Carman RJ, Van Tassell RL, Kingston DGI, Bashir M, Wilkins TD. 1988. Conversion of IQ, a dietary pyrolysis carcinogen, to a direct-acting mutagen by normal intestinal bacteria of human. Mut Res 206: 335-342. Chadwick RW, George SE, Claxton LD. 1992. Role of gastrointestinal mucosa and microflora in the bioactivation of dietary and environmental mutagens or carcinogens. Durg Metab Rev 24: 425-492. Champagne CP, Gardner NJ. 2005. Challenges in the addition of probiotic cultures to foods. Crit Rev Food Sci Nutr 45: 61-84. Chen RM, Wu JJ, Lee SC, Huang AH, Wu HM. 1999. Increase of intestinal Bifidobacterium and suppression of coliform bacteria with short-term yogurt ingestion. J Dairy Sci 82: 2308-2314. Chung KT, Anderson GM, Fulk GE. 1975. Formation of indole acetic acid by intestinal anaerobes. J Bacteriol 124: 573-575. Collier SW, Storm JE, Bronaugh RL. 1993. Reduction of azo dyes during in vitro percutaneous absorption. Toxicol Appl Pharmacol 118: 73-79. Collins EB, Hall BJ. 1984. Growth of bifidobacteria in milk and preparation of Bifidobacterium infantis of a dietary adjunct. J Dairy Sci 67: 1376-1380. Collins JK, Thornton G, Sullivan GO. 1998. Selection of probiotic strains for human applications. Int Dairy J 8: 487-490. Collins MD, Gibson GR. 1999. Probiotics, prebiotics, and synbiotics: Approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 69: 1052S-1057S. Commane D, Hughes R, Shortt C, Rowland I. 2005. The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mutat Res 591: 276-289. Dave RI, Shah NP. 1998. Ingredient supplementation effects on viability of probiotic bacteria in yogurt. J Dairy Sci 81: 2804-2816. Deguchi Y, Morishita T, Mutai M. 1985. Comparative studies on synthesis of water-soluble vitamins among human species of bifidobacteria. Agric Biol Chem 49: 13-19. De Kok TM, van Maanene JM. 2000. Evaluation of fecal mutagenicity and colorectal cancer risk. Mutat Res 463: 53-101. De Roos NM, Katan MB. 2000. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: A review of papers published between 1988 and 1998. Am J Clin Nutr 71: 405-411. De Vries W, Stouthamer AH. 1968. Pathway of glucose fermentation in relation to the taxonomy of bifidobacteria. J Bacteriol 93: 574-576. De Vries W, Stouthamer AH. 1969. Factors determining the degree of anaerobiosis of Bifidobacterium strains. Arch Mikrobiologie 65: 275-287. Eisenbrand G, Tang W. 1993. Food-borne heterocyclic amines. Chemistry formation, occurrence and biological activities. A literature review. Toxicology 84: 1-82. Elsden SR, Hilton MG, Walker JM. 1976. The end products of the metabolism of aromatic amino acids by clostridia. Arch Microbiol 107: 283-288. Ericsson CD. 2003. Traveller’s diarrhea. Int J Antimicrob Agents 21: 116-124. Felton JS, Knize MG. 1991. Occurrence, identification and bacterial mutagenicity of heterocyclic aromatic amines in cooked food. Mutat Res 259: 205-217. Fooks LJ, Gibson GR. 2002. Probiotics as modulators of the gut flora. Br J Nutr 88: S39-S49. Freudenheim JL, Graham S, Horvath PJ, Marshall JR, Haughey BP, Wilinson G. 1990. Risks associated with source of fiber and fiber components in cancer of the colon and rectum. Cancer Res 50: 3295-3300. Fujii T, Yokoyama H, Hamamoto H, Yoon SH, Hori H. 1995. Applications of MTT assay to primary cultured rat hepatocytes. Biol Pharm Bull 18: 1446-1449. Fujiwara S, Hashiba H, Hirota T, Forstner JF. 1997. Proteinaceous factor in culture supernatant fluids of bifidobacteria which prevents the binding of enterotoxigenic Escherichia coli to gangliotetraosylceramide. Appl Environ Microbiol 63: 506-512. Fukushima Y, Li ST, Hara H, Terada A, Mitsuoka T. 1997. Effect of follow-up formula containing bifidobacteria (NAN BF) on fecal flora and fecal metabolites in healthy children. Biosci Microflora 16: 65-72. Fuller R. 1989. Probiotics in man and animals. J Appl Bacteriol 66: 365-378. Fuller R, Gibson GR. 1997. Modification of the intestinal microflora using probiotics and prebiotics. Scand J Gastroenterol Suppl 222: 28-31. Gibson GR. 1998. Dietary modulation of the human gut microflora using prebiotcs. Br J Nutr 80: S209-S212. Gibson GR, McCartney AL. 1998. Modification of the gut flora by dietary means. Biochem Soc Trans 26: 222-228. Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 125: 1401-1402. Gibson GR, Wang X. 1994. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 77: 412-420. Gomes AMP, Malcata FX. 1999. Bifidobacterium spp. and Lactobacillus acidophilus: biological, biochemical, technological and therapeutical properties relevant for use as probiotics. Trend Food Sci Technol 10: 139-157. Gopal PK, Prasad J, Gill HS. 2003. Effect of the consumption of Bifidobacterium lactics HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutr Res 23: 1313-1328. Granum PE. 1990. Clostridium perfringenes toxins involved in food poisoning. Int J Food Microbiol 10: 101-112. Gross GA, Turesky RJ, Fay LB, Stillwell WG, Skipper PL, Tannenbaum SR. 1993. Heterocyclic aromatic amine formation in grilled bacon, beef and fish and in grill scrapings. Carcinogenesis 14: 2313-2318. Guarner F. 2006. Enteric flora in health and disease. Digestion 73: 5-12. Guarner F, Malagelada JR. 2003. Gut flora in health and disease. Lancet 361: 512-519. Hamann C, Samalouti VEL, Ulmev AJ, Flad HD, Rietschel ET. 1998. Components of gut bacteria as immunomodulators. Int J Food Microbiol 41: 141-154. Harmon SM, Kautter DA, Peeler JT. 1971. Comparison of media for enumeration of Clostridium perfringens. Appl Microbiol 21: 922-927. Hauschild AHW, Hilsheimer R. 1974. Evaluation and modifications of media for enumeration of Clostridium perfringens. Appl Microbiol 27: 78-82. Hauschild AHW, Hilsheimer R, Griffith DW. 1974. Enumeration of fecal Clostridium perfringens spores in egg yolk-free tryptose-sulfite-cycloserine agar. Appl Microbiol 27: 527-530. Hawrelak JA, Myers SP. 2004. The causes of intestinal dysbiosis: A review. Altern Med Rev 9: 180-197. Hill RJ. 1975. The role of colon anaerobes in the metabolism of bile acids and steroids and relationship to colon cancer. Cancer 36: 2387-2400. Holzapfel WH, Haberer P, Snel J, Schillinger U. 1998. Overview of gut flora and probiotics. Int J Food Microbiol 41: 85-101. Hose H, Sozzi T. 1991. Biotechnology group meeting probiotics-fact or fiction. J Chem Technol Biotech 51: 540-544. Hosono A, Otani H, Yasui H, Watanuki M. 2002. Impact of fermented milk on human health: Cholesterol-lowering and immunomodulatory properties of fermented milk. Ani Sci J 73: 241-256. Hughes DB, Hoover DG. 1995. Viability and enzymatic activity of bifidobacteria in milk. J Dairy Sci 78: 268-276. Hughes R, Rowland IR. 2000. Metabolic activities of the gut microflora in relation to cancer. Microb Ecol Health Dis Suppl 2: 179-185. Ishibashi N, Yaeshima T, Hayasawa H. 1997. Bifidobacteria: their significance in human intestinal health. Mal J Nutr 3: 149-159. Ishibashi N, Yamazaki S. 2001. Probiotics and safety. Am J Clin Nutr 73: S465-S470. Jao YC, Mikolajcik EM, Hansen PMT. 1978. Growth of Bifidobacterium bifidum var. Pennsylvanicus in laboratory media supplemented with amino sugars and spent broth from Escherichia coli. J Food Sci 43: 1257-1263. Jiang T, Mustapha A, Savaiano DA. 1996. Improve of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J Dairy Sci 79: 750-757. Kabeir BM, Abd-Aziz S, Muhammad K, Shuhaimi M, Yazid AM. 2005. Growth of Bifidobacterium longum BB536 in media (fermented cereal porridge) and their survival during refrigerated storage. Lett Appl Microbiol 41: 125-131. Kailasapathy K, Chin J. 2000. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol 78: 80-88. Kieran JA, Curt MJ, Schermer CR. 2003. Institutional variations in the management of patients with acute appendicitis. J Gastrointest Surg 7: 523-528. Kikugawa K, Kato T. 1986. Formation of a mutagenic diazoquinone by interaction of phenol with nitrite. Food Chem Toxicol 26: 209-214. Kitahara M, Takamine F, Imamura T, Benno Y. 2000. Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpaha-dehydroxylating activity to Clostrididum scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 50: 971-978. Klaver FAM, Kingma F, Weerkamp AH. 1993. Growth and survival of bifidobacteria in milk. Ned Milk and Dairy J 47: 151-164. Knasmüller S, Steinkellner H, Hirschl AM, Rabot S, Nobis EC, Kassie F. 2001. Impact of bacteria in dairy products and of the intestinal microflora on the genotoxic and carcinogenic effects of heterocyclic aromatic amines. Mutat Res 480: 129-138. Konsoula R, Barile FA. 2005. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro 19: 675-684. Kullen MJ, Khil J, Busta FF, Gallaher DD, Brady LJ. 1998. Carbohydrate source and bifidobacteria influence the growth of Clostridium perfringenes in vivo and in vitro. Nutr Res 18: 1889-1897. Kurmann JA, Rasic JL. 1991. The health potential of products containing Bifidobacteria. In: Robison RK, editors. Therapeutic Properties of Fermented Milks. London: Elsevier. pp. 117-157. Latta RK, Fiander H, Ross NW, Simpson C, Schneider H. 1993. Toxicity of bile acids to colon cancer cell lines. Cancer Lett 70: 167-173. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. 1995. Cancer risk of heterocyclic aromatic amines in cooked foods: An analysis and implication for research. Carcinogenesis 16: 39-52. Lepercq P. 2004. Bifidobacterium animalis DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand J Gastroenterol. 39: 1266-1271. Lesuffleur T, Kornowski A, Luccioni C, Muleris M, Barbat A, Beaumatin J, Dussaulx E, Dutrillaux B, Zweibaum A. 1991. Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation. Int J Cancer 49: 721-730. Lievin V, Peiffer I, Hudault S. 2000. Bifidobacterium stains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47: 646-652. Lilly DM, Stillwell RH. 1965. Probiotics: Growth-promoting factors produced by microorganisms. Sci 147: 747-748. Lin YJ, Rhee JC, Bae YM, Chun WJ. 2007. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J Gastroenterol 13: 1947-1952. Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschlimann JM. 1994. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 10: 55-63. Lizoko NN. 1987. Stress and intestinal microflora. Nahrung 31: 443-447. MacFarlane GT, Cummings JH. 1991. The colonic flora, fermentation and large bowel digestive function. In: Phillips SF, Pemberton JH, Shorter RG, editors. The large intestine: physiology, pathophysiology and disease. New York: Raven Press Ltd. MacFarlane GT, Cummings JH, Allison C. 1986. Protein degradation by human intestinal bacteria. J Gen Microbiol 132: 1647-1656. Massey RC, Key PE, Mallett AK, Rowland IR. 1988. An investigation of the endogenous formation of apparent total N-nitroso compounds in conventional microflora and germ-free rats. Food Chem Toxicol 26: 595-600. Mata LJC, Carrillo C, Millatoro E. 1969. Fecal microflora in healthy persons in a preindustrial region. Appl Microbiol 17: 596-602. Matsumoto M, Ohishi H, Benno Y. 2001. Impact of LKM512 yogurt on improvement of intestinal environment of the elderly. FEMS Immunol Med Microbiol 31: 181-186. Meal PF, Cocker J, Wilson HK, Gilmour JM. 1981. Search for benzidine and its metabolites in urine of workers weighing benzidine derived dyes. Br J Ind Med 38: 191-193. Mitsuoka T. 1990. Bifidobacteria and their role in human health. J Ind Microbiol 6: 263-268. Mitsuoka T. 1996. Intestinal flora and human health. Asia Pacific J Clin Nutr 5: 2-9. Moore WEC, Holdeman LV. 1975. Discussion of current bacteriological investigations of the relationships between intestinal flora, diet and colon cancer. Cancer Res 35: 3418. Moreno Y, Collando MC, Ferrús MA, Cobo J M, Hernández E, Hernández M. 2006. Viability assessment of lactic acid bacteria in commercial dairy products at 4℃using LIVE/DEAE® BacLight TM staining and conventional plate counts. Int J Food Sci Technol 41: 275-280. Morotomi M, Mutai M. 1986. In vitro binding of potent mutagenic pyrolyzates to intestinal bacteria. J Natl Cancer Inst 77: 195-201. Mortazavian AM, Ehsani MR, Mousavi SM, Emam-djomeh Z, Sohrabvandi, Rezaei K. 2007. Effect of refrigeration temperature on the viability of probiotics in yogurt. Int J Dairy Technol 60: 123-127. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survivial: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63. Munoa FJ, Pares R. 1988. Selective medium for isolation of enumeration of Bifidobacterium spp. Appl Environ Microbiol 54: 1715-1718. Mutai M, Tanaka R. 1987. Ecology of Bifidobacterium in human intestinal flora. Bifidobacteria Microflora 6: 33-41. Nagengast FM, Grubben MJAL, van Munster IP. 1995. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 31: 1067-1070. Naidu AS, Bidlack WR, Clemens RA. 1999. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 39: 13-126. Nanno M, Morotomi H, Takayama H, Kuroshima T, Takana R, Mutai M. 1986. Mutagenic activity of biliary metabolites of benzo[a]pyrene by β-glucuronidase positive bacteria in human faeces. J Med Microbiol 22: 351-355. Newmark HL, Lupton JR. 1990. Determinants and consequences of colonic luminal pH: implications for colon cancer. Nutr Cancer 14: 161-173. O’Sullivan DJ, Kullen MJ. 1998. Tracking of probiotic bifidobacteria in the intestine. Int Dairy J 8: 513-525. O’Sullivan MG. Thornton G, Osullivan GC, Collins JK. 1992. Probiotic bacteria: myth or reality? Trends Food Sci Technol 3: 309-314. Oberreuther-Moschner DL, Jahreis G, Rechkemmer G, Pool-Zobel BL. 2004. Dietary intervention with the probiotics Lactobacillus acidophilus 145 and Bifidobacterium longum 913 modulates the potentical of human faecal water to induce damage in HT29clone19A cells. Br J Nutr 91: 925-932. Ohgaki H, Takayama S, Sugimura T. 1991. Carcinogenecities of heterocyclic amines. Mut Res 259: 399-411. Ohkami H, Tazawa K, Yamashita I, Shimizu T, Murai K, Kobashi K, Fujimarki M. 1995. Effects of apple pectin on fecal bacterial enzymes in azoxymethane-induced rat colon carcinogenesis. Jpn J Cancer Res 86: 523-529. Olivares M, Díaz-Ropero MP, Gómez N, Lara-Villoslada F, Sierra S, Maldonado JA, Martín R, López-Huertas E, Rodríguez JM, Xaus J. 2006. Oral intake of two probiotic strains, Lactobacillus gasseri CETC5711, enhances the intestinal function of healthy adults. Int J Food Microbiol 107: 114-111. Ouwehand AC, Isolauri E, Kirjavainene PV, Salminen SJ. 1999. Adhesion of four Bifidobacterium strains to human intestinal mucus from subjects in different age groups. FEMS Microbiol Lett 172: 61-64. Ouwehand AC, Salminen S, Tölkkö S, Roberts P, Ovaska J, Salminen E. 2002. Resected human colonic tissue: New model for characterizing adhesion of lactic acid bacteria. Clin Diagn Lab Immunol 9: 184-186. Pence BC, Landers M, Dunn DM, Shen CL, Miller MF. 1998. Feeding of a well cooked beef diet containing a high heterocyclic amine content enhances colon and stomach carcinogenesis in 1,2-dimethylhydrazine treated rats. Nutr Cancer 30: 220-226. Plumb JA, Milroy R, Kaye SB. 1989. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49: 4435-4440. Plummer SM, Grafstrom RC, Yang LL, Curren RD, Linnainmaa K, Harris CC. 1986. Fecapentaene-12 causes DNA damage and mutations in human cells. Carcinogenesis 7: 1607-1609. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. 2004. Clostridium difficile pilot study: effect of probiotic supplementation on the incidence of C. difficile diarrhea. Int Microbiol 7: 59-62. Poupard JA, Husain I, Norris RF. 1973. Biology of the bifidobacteria. Bacteriol Rev 37: 136-165. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. 1990. Increased cell division as a cause of human cancer. Cancer Res 50: 7415-7421. Prival MJ, Davis VM, Peiperl MD, Bell SJ. 1988. Evaluation of azo food dyes for mutagenicity and inhibition of mutagenicity by methods using Salmonella typhimurium. Mutat Res 206: 247-259. Radley S, Pongracz J, Lord J, Neoptolemos JP. 1996. Bile acids and colorectal cancer. Cancer Top 10: 1-7. Rafii F, Cerniglia CE. 1995. Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect 5: 17-19. Rafii F, Franklin W, Cerniglia CE. 1990. Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora. Appl Environ Microbiol 56: 2146-2151. Rafii F, Franklin W, Heflich RH, Cerniglia CE. 1991. Reduction of nitroaromatic compounds by anaerobic bacteria isolated from the human gastrointestinal tract. Appl Environ Microbiol 57: 962-968. Rafii FH, Hall JD, Cerniglia CE. 1997. Mutagenicity of azo dyes used in foods, drugs and cosmetics before and after reduction by Clostridium species from the human intestinal tract. Food Chem Texicol 35: 897-901. Rafter J. 2003. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 17: 849-859. Rafter JJ, Child P, Anderson AM, Alder R, Eng V. 1987. Cellular toxicity of fecal water depends on diet. Am J Clin Nutr 45: 559-563. Reddy BS, Rivenson A. 1993. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen. Cancer Res 53: 3914-3918. Roberton AM. 1993. Roles of endogenous substances and bacteria in colorectal cancer. Mutat Res 290: 71-78. Rogosa M. 1974. Bergey’s Manual of Determinative Bactiology, 7 th ed. In: Buchanan RE, Gibbons NE editors. Baltimore: Williams and Wilkins Co., pp. 669-676. Rowland IR. 1995a. Interaction of gut flora with metal compounds. In: Hill MJ, editors. Role of Gut Bacteria in Human Toxicology and Pharmacology. London: Taylor and Francis. pp. 197-211. Rowland IR. 1995b. Toxicology of the colon: Role of the intestinal microflora. In: Human colonic bacteria. In: Gibson GR, McFarlane GT, editors. Role in Nutrition, Physiology and Pathology. Boca Raton, FL: CRC Press. pp. 155-174. Rowland IR, Granli T, Bockman OC, Key PE, Massey RC. 1991. Endogenous N-nitrosation in man assessed by measurement of apparent total N-nitroso compound in faeces. Carcinogenesis 12: 1395-1401. Rowland IR, Mallett AK, Wise A. 1985. The effect of diet on the mammalian gut flora and its metabolic activities. CRC Crit Rev Toxicol 16: 31-103. Rumney CJ, Rowland IR, O’Neill IK. 1993. Conversion of IQ to 7-OHIQ by gut microflora. Nutr Cancer 19: 67-76. Saarela M, Virkajärvi I, Alakomi HL, Sigvart-Mattila P, Mättö J. 2006. Stability and functionality of freeze-dried probiotic Bifidobacterium cells during storage in juice and milk. Int Dairy J 16: 1477-1482. Saavedra JM, Bauman NA, Oung I, Oerman JA, Yolken RH. 1994. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 344: 1046-1049. Saito Y, Hamanaka Y, Saito K, Benno Y. 2002. Stability of species composition of fecal bifidobacteria in human subjects during fermented milk intake. Cur Microbiol 44: 368-373. Saito Y, Takano T, Rowland IR. 1992. Effects of soybean oligosaccharides on the human gut microflora in in vitro culture. Microb Ecol Health Dis 5: 105-110. Salminen S, Bouley C, Boutron-Ruault MC, Cumming JH, Franck A, Gibson GR, Isolauri E, Moreau MC, Roberforid M, Rowland I. 1998a. Function food science and gastrointestinal physiology and function. British J Nutr 80: S147-S171. Salminen S, Isolauri E, Salminen E. 1996. Probiotics and stabilization of the gut mucosal barrier. Asia Pac J Clin Nutr 5: 53-56. Salminen S, Ouwehand AC, Isolauri E. 1998b. Clinical application of probiotic bacteria. Int Dairy J 8: 563-572. Samona A, Robinson RK. 1994. Effect of yogurt cultures on the survival of bifidobacteria in fermented milks. J Soc Dairy Technol 47: 58-60. Sanders ME. 1994. Lactic acid bacteria as promoters of human health. In: Goldberg I, editors. Functional foods. New York: Chapman and Hall. p 305-322. Sanders ME, Walker DC, Walker KM, Aoyama K, Klaenhammer TR. 1996. Performance of commercial cultures in fluid milk applications. J Dairy Sci 79: 943-955. SAS. 2003. Statistics 9.1 ed. SAS Institute Inc., Cary, NC, U.S.A. Scardovi V. 1986. The genus Bifidobacterium. In: Holt JG, editors. Bergey’s Manual of Systematic Bacteriology. Vol. 2. Baltimore: Williams and Wilkins Co., pp. 1418-1434. Schiffman MH, Van Tussell RL, Robinson A. 1989. Case control study of colorectal cancer and fecapentaene excretion. Cancer Res 49: 1322-1326. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. 1995. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 78: 491-497. Schrezenmeir J, De Vrese M. 2001. Probiotics, prebiotics, and synbiotics: Approaching a definition. Am J Clin Nutr 73: 361S-364S. Schut HA, Snyderwine EG. 1999. DNA adducts of heterocyclic amine food mutagens: Implications for mutagenesis and carcinogenesis. Carcinogenesis 20: 353-368. Servin AL. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28: 405-440. Shahidi SA, Ferguson AR. 1971. New quantitative, qualitative, and confirmatory media for rapid analysis of food for Clostridium perfringens. Appl Microbiol 21: 500-506. Shekels LL, Lyftogt CT, Ho XB. 1996. Bile acid-induced alterations of mucin production in differentiated human colon cancer cell lines. Int J Biochem Cell Biol 28: 193-201. Silvester KR, Bingham SA, Pollock JRA, Cummings JH, O’Neill IK. 1997. Effect of meat and resistant starch on faecal excretion of apparent total N-nitroso compounds and ammonia from the human large bowel. Nutr Cancer 29: 13-23. Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, S.Reddy B. 1997. Bifidobaceterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermedidate biomarkers of colon carcinogenesis. Carcinogenesis 18: 833-841. Smith EA, Macfarlane GT. 1996. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol 81: 288-302. Steer T. 2000. Perspectives on the role of the human gut microbiota and its modulation by pro- and prebiotics. Nutr Res Rev 13: 229-254. Tahri K, Grill JP, Schneider F. 1997. Improvement of trihydroxyconjugated bile salts in cholesterol assimilation by bifidobacteria. Curr Microbiol 21: 149-151. Takada H, Hirook T, Hiramatasu Y, Yamamato M. 1982. A model for activation of dietary glycosides to mutagens by intestinal flora. Cancer Res 42: 331-334. Talwalkar A, Kailasapathy K. 2004. A review of oxygen toxicity in probiotic yogurts: Influence on the survivial of probiotic bacteria and protective techniques. Compr Rev Food Sci Food Saf 3: 117-124. Tamine AY, Marshall VME, Robinson RK. 1995. Microbiological and technological aspects of milks fermented by bifidobacteria. J Dairy Res 62: 151-187. Tannock GW. 1998. Studies of the intestinal microflora: A prerequisite for the development of probiotics. Int Dairy J 8: 527-533. Tannock GW, Bateup JM, Jenkinson HF. 1997. Effect of sodium taurocholate on the in vitro growth of lactobacilli. Microb Ecol 33: 163-167. Tsuda M, Negishi C, Makino R, Sato S, Yamaizumi Z, Hirayama T, Sugimura T. 1985. Use of nitrite and hypochlorite treatments in determination of the contributions of IQ-type and non-IQ-type heterocyclic amines to the mutagenicities in crude pyrolyzed materials. Mutat Res 147: 335-341. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. 2003. Using probiotics and prebiotics to improve gut health. Drug Discov Today 8: 692-700. Van Houte J, Gibbons RJ. 1966. Studies of the cultivable flora of normal human faeces. Antonie Van Leeuwenhoek 32: 212. Van Loo J, Cummings J, Delzenne N, Englyst H, Franck A, Hopkins M, Kok N, Macfarlane G, Newton D, Quigley M, Roberfroid M, van Vliet T, van den Heuvel E. 1999. Functional food properties of non-digestible oligosaccharides. Br J Nutr 81: 121-132. Ventura M, van Sinderen D, Fitzgerald GF, Zink R. 2004. Insights into the taxonomy, genetics and physiology of bifidobacteria. Antonie Van Leeuwenhoek 86: 205-223. Venturi M, Hambly B, Glinghammer B, Rafter JJ, Rowland IR. 1997. Genotoxic activity in human faecal water and the role of bile acids: A study using the alkaline comet-assay. Carcinogenesis 18: 2353-2359. Visek WJ. 1978. Diet and cell growth modulation by ammonia. Am J Clin Nutr 31: S216-S220. Wakabayashi K, Ushiyama H, Takahashi M, Nukaya H, Kim SB, Hirose M, Ochiai M, Sugimura T, Nagao M. 1993. Exposure to heterocyclic aromatic amines. Environ Health Perspect 29: 129-134. Woods JA, Dunne C, Collins JK, Shanahan F, O’Brien NM. 2002. Genotoxicity of fecal water in a free-living Irish population. Nutr Cancer 42: 62-69. Yi W, Fischer J, Krewer G, Akoh CC. 2005. Phenolic compounds from blueberries can inhibit colon cancer cell proliferation and induce apoptosis. J Agric Food Chem 53: 7320-7329. Young, TB, Wolf DA. Case-control study of proximal and distal colon cancer and diet in Wisconsin. 1988. Int J Cancer 42: 167-175. Ziemer CJ, Gibson GR. 1998. An overview of probiotics, prebiotics and synbiotics in the functional food concept: perspectives and future strategies. Int Dairy J 8: 473-479. Zoetendal EG, Cheng B, Koike S, Mackie RI. 2004. Molecular microbial ecology of the gastrointestinal tract: from phylogeny to function. Curr Issues Intest Microbiol 5: 31-47. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28078 | - |
dc.description.abstract | 摘要
人體腸道菌相十分複雜,其中有益菌雙叉桿菌(bifidobacteria)與有害菌產氣莢膜梭菌(Clostridium perfringens)菌數的消長,與人體健康關係十分密切。本試驗探討攝食雙叉桿菌鮮乳在四週的試驗期間對24位健康成人腸道菌相、糞便水份含量、pH值及其萃取液對細胞毒性之影響。試驗分成四個時期,第一期為飲食調整期,第二、三期為攝食雙叉桿菌鮮乳的前期與後期,第四期為排空期。另外再進行二十天之雙叉桿菌鮮乳儲存安定性試驗,探討在一般的儲存溫度與運送過程溫度變動下,對雙叉桿菌鮮乳品質的影響。 結果顯示,攝食雙叉桿菌鮮乳可使受試者腸道中雙叉桿菌顯著增加(p < 0.05);而腸道有害菌產氣莢膜梭菌顯著減少(p < 0.05)。試驗期間受試者糞便檢體的水分含量、pH值無統計上的差異,且受試者的身高、體重、BMI值及血液生化值均無顯著變化,皆在標準範圍內(p > 0.05)。 接著以MTT細胞存活分析法,測定糞便檢體萃取液對腸道細胞株Caco-2及HT-29之細胞毒性。結果顯示,低濃度之糞便檢體萃取液對腸道細胞不具毒性,在雙叉桿菌鮮乳攝食期間,可顯著降低高濃度糞便檢體萃取液對腸道細胞的毒性(p < 0.05)。顯示攝食雙叉桿菌鮮乳,不會對受試者生理上造成不良的影響。可有效增加腸道益菌數,減少害菌數,並降低糞便中毒性物質對腸道細胞的傷害,具改善腸道健康之功能。 雙叉桿菌鮮乳儲存安定性試驗結果顯示,含菌量6.63 log CFU/mL之雙叉桿菌鮮乳,在一般鮮乳十天之保存期限內,儲存溫度不論是在4℃或11℃,其雙叉桿菌活菌數皆大於6.2 log CFU/mL,pH值維持在6.7-6.8,可滴定酸度為0.1%,皆正常範圍之內,在保存期間生化特性穩定,品質安定。 | zh_TW |
dc.description.abstract | Abstract
The human gastrointestinal is a complex ecosystem, the balance of beneficial bacteria bifidobacteria and harmful Clostridium perfringens is highly related to human health. This study was conducted to investigate the effect of intake fresh milk plus Bifido® on the intestinal microflora, fecal water content, pH values and fecal extracts cytotoxicity on Caco-2 and HT-29 in 24 healthy adults. Furthermore, the changes of viable bifidobacteria, pH value and titratable acidity in fresh milk plus Bifido® store at 4℃ and 11℃ for 20 days were also studied. Results indicated that intake the fresh milk plus Bifido® significantly increased the colony counts of fecal bifidobacteria (p < 0.05), decreased the growth of C. perfringens (p < 0.05) and significantly increased the log number ratio of bifidobacteria to C. perfringens (p < 0.05). Subjects’ height, weight, BMI, blood parameters, fecal water content and fecal pH had no apparent changes during experimental period. Each period of subjects’ fecal extracts at low concentrations were no cytotoxicity on Caco-2 and HT-29. The cytotoxicity of subjects’ fecal extracts at high concentrations on Caco-2 and HT-29 were significantly reduced during fresh milk plus Bifido® intake periods (p < 0.05). These results suggested that intake the fresh milk plus Bifido® were beneficial in improving the intestinal flora and decreasing cytotoxic materials in the intestinal tract of health adults. Fresh milk plus Bifido® contains 6.63 log CFU/mL bifidobacteria. The survival number of bifidobacteria in fresh milk plus Bifido® was maintained at 6.2 log CFU/mL during 10 days of shelf life time. The changes of pH value and titratable acidity in fresh milk plus Bifido® did not change statistically during the experimental period (p > 0.05). | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:00:49Z (GMT). No. of bitstreams: 1 ntu-96-R94641005-1.pdf: 2404724 bytes, checksum: d675ecedcdffd3d9dc43d59feaccabec (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 目 錄
頁次 第一章 總論..………………………………………………… 1 壹、 前言…………………………………………………… 1 貳、 文獻整理……………………………………………… 2 一、 人體消化道菌群分佈………………………………… 2 (一) 腸道菌相之簡介……………………………………… 2 (二) 影響腸道菌相之因素………………………………… 7 二、 腸道菌相與健康……………………………………… 9 (一) 腸道菌相的功效……………………………………… 9 (二) 腸內物質的組成……………………………………… 10 (三) 腸道細菌代謝造成的毒性影響……………………… 13 (四) 測定大腸功能的方法………………………………… 19 三、 益生菌之簡介………………………………………… 22 (一) 雙叉桿菌的介紹……………………………………… 22 (二) 雙叉桿菌之營養機能及健康功效………………………24 第二章 攝食雙叉桿菌鮮乳對腸道菌相與Caco-2及HT-29毒性 之影響………29 壹、 實驗架構……………………………………………… 29 貳、 材料與方法…………………………………………… 33 一、 實驗材料……………………………………………… 33 (一) 雙叉桿菌鮮乳………………………………………… 33 (二) 藥品…………………………………………………… 33 (三) 器材…………………………………………………… 33 (四) 試驗細胞株…………………………………………… 34 (五) 培養基………………………………………………… 34 二、 人體試驗之設計……………………………………… 35 (一) 受試者………………………………………………… 35 (二) 試驗設計…………………………………………………35 (三) 飲食控制與飲食記錄………………………………… 36 三、 人體試驗之方法……………………………………… 36 (一) 培養基………………………………………………… 36 (二) 取樣及微生物檢測…………………………………… 37 (三) 水分含量……………………………………………… 38 (四) pH測定……………………………………………………38 四、 糞便檢體萃取液細胞毒性試驗之方法…………………38 (一) 製備培養基…………………………………………… 38 (二) 細胞的解凍活化……………………………………… 38 (三) 細胞培養……………………………………………… 38 (四) 細胞繼代……………………………………………… 39 (五) 細胞株的保存………………………………………… 39 (六) 細胞數計數…………………………………………… 39 (七) 糞便檢體萃取液之製備……………………………… 40 (八) 糞便檢體萃取液對人類結腸癌細胞株Caco-2及HT-29之毒 性試驗… 40 五、 統計分析……………………………………………… 41 參、 結果與討論…………………………………………… 41 一、 試驗期間受試者血液生化值及每日營養素平均攝取量 ……………41 二、 攝食雙叉桿菌鮮乳對受試者糞便中雙叉桿菌之影 響…………42 三、 攝食雙叉桿菌鮮乳對受試者糞便中產氣莢膜梭菌之 影響………43 四、 攝食雙叉桿菌鮮乳對受試者糞便中雙叉桿菌及產氣莢膜梭 菌菌數對數比值之影響……………………………… 44 五、 攝食雙叉桿菌鮮乳對受試者糞便水分含量及pH值之影 響……………44 六、 攝食雙叉桿菌鮮乳之受試者糞便檢體萃取液對Caco-2及 HT-29細胞毒性試驗………………………………………44 肆、 結論…………………………………………………… 46 第三章 雙叉桿菌鮮乳儲存安定性試驗……………………… 62 壹、 實驗架構……………………………………………… 65 貳、 材料與方法…………………………………………… 64 一、 實驗材料……………………………………………… 64 (一) 雙叉桿菌鮮乳………………………………………… 64 (二) 器材…………………………………………………… 64 二、 培養基………………………………………………… 64 三、 實驗方法……………………………………………… 64 (一) 雙叉桿菌鮮乳之雙叉桿菌數測定…………………… 64 (二) 雙叉桿菌鮮乳pH值之測定………………………………65 (三) 雙叉桿菌鮮乳酸度之測定…………………………… 65 四、 統計分析……………………………………………… 65 參、 結果與討論…………………………………………… 65 一、 雙叉桿菌鮮乳之雙叉桿菌菌數變化情形…………… 65 二、 雙叉桿菌鮮乳之pH值及酸度變化情形……………… 66 肆、 結論…………………………………………………… 66 參考文獻…………………………………………………………… 70 附錄………………………………………………………………… 85 附錄一、 受試者基本資料……………………………………… 85 附錄二、 糞便性質問卷................................. 86 附錄三、 飲食習慣問卷................................. 88 附錄四、 實驗後測問卷………………………………………… 89 附錄五、 飲食紀錄範例............................... 91 附錄六、 臺灣保健食品學會同意臨床試驗證明書-雙叉桿菌鮮乳 (中文)……………… 92 附錄七、 臺灣保健食品學會同意臨床試驗證明書-雙叉桿菌鮮乳 (英文)……………… 93 | |
dc.language.iso | zh-TW | |
dc.title | 攝食雙叉桿菌鮮乳對腸道菌相與Caco-2及HT-29毒性之影響 | zh_TW |
dc.title | Effects of fresh milk plus Bifido® intake on the
intestinal microflora and cytotoxicity on Caco-2 and HT-29 | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周正俊,蔡國珍,潘崇良,丘志威 | |
dc.subject.keyword | 腸道菌相,雙叉桿菌,產氣莢膜梭菌,細胞毒性,存活率, | zh_TW |
dc.subject.keyword | Intestinal flora,bifidobacteria,Clostridium perfringens,Cytotoxicity,Viability, | en |
dc.relation.page | 84 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-31 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
Appears in Collections: | 食品科技研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-96-1.pdf Restricted Access | 2.35 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.